The estimated Net Worth of Mark T. Roskey is at least $922 Tisíc dollars as of 1 April 2022. Mr. Roskey owns over 171 units of Quanterix Corp stock worth over $269,463 and over the last 7 years he sold QTRX stock worth over $332,833. In addition, he makes $319,696 as Senior Vice President - Commercial and Accelerator at Quanterix Corp.
Mark has made over 44 trades of the Quanterix Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 171 units of QTRX stock worth $5,094 on 1 April 2022.
The largest trade he's ever made was selling 5,093 units of Quanterix Corp stock on 30 March 2020 worth over $91,623. On average, Mark trades about 760 units every 22 days since 2018. As of 1 April 2022 he still owns at least 22,325 units of Quanterix Corp stock.
You can see the complete history of Mr. Roskey stock trades at the bottom of the page.
Mark T. Roskey serves as Senior Vice President - Commercial and Accelerator of the Company. He has been our Senior Vice President, Commercial and Accelerator since March 2019 and served as Senior Vice President and General Manager of Applications and Reagents from September 2014 to March 2019. Prior to joining us, Dr. Roskey served as Vice President and General Manager of the America's Sales and Service organization in PerkinElmer's Life Science and Technologies Division from December 2011 to September 2014. PerkinElmer is a global life science company. Prior to PerkinElmer, Dr. Roskey served as Senior Vice President of Biology Research and Development at Caliper Life Sciences, Inc. from March 2009 to November 2011, when it was acquired by PerkinElmer. At Caliper Life Sciences, Inc., Dr. Roskey served as Senior Vice President of Applied Biology Research from 2008 to 2011 and Vice President of Worldwide Marketing from July 2003 to 2008. Prior to that, Dr. Roskey served as Vice President of Worldwide Marketing for Zymark Corporation, a laboratory automation company, from December 2001 to August 2003 when it was acquired by Caliper Life Sciences, Inc. Prior to that, Dr. Roskey served as Director of Marketing at Applied Biosystems, Inc. Dr. Roskey completed a postdoctoral fellowship in molecular immunobiology at the Harvard Medical School and has a Ph.D. in microbiology from the University of Notre Dame and a B.S. in biology from Framingham State University.
As the Senior Vice President - Commercial and Accelerator of Quanterix Corp, the total compensation of Mark Roskey at Quanterix Corp is $319,696. There are 7 executives at Quanterix Corp getting paid more, with E. Kevin Hrusovsky having the highest compensation of $3,631,000.
Mark Roskey is 60, he's been the Senior Vice President - Commercial and Accelerator of Quanterix Corp since 2019. There are 7 older and 12 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.
Mark's mailing address filed with the SEC is C/O QUANTERIX CORPORATION,, 900 MIDDLESEX TURNPIKE, BILLERICA, MA, 01821.
Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister a Keith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
Quanterix Corp executives and other stock owners filed with the SEC include: